Viatris Inc
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Viatris is rated a Sell due to persistent risks, weak financials, and a likely profit-taking event post-Q2 2026 earnings. Read more on VTRS stock here.
Viatris Receives EMA CHMP Recommendation For Approval Of Ruxolitinib Viatris For The Treatment Of Myelofibrosis, Polycythaemia Vera And Graft-Vs-Host Disease
https://www.ema.europa.eu/en/medicines/human/EPAR/ruxolitinib-viatris
Viatris’ Quarterly Earnings Preview: What You Need to Know
Viatris is scheduled to report its second-quarter results next month, with Wall Street expecting earnings per share to remain roughly unchanged from a year ago.
Congressional Trades in $VTRS
Insider Trades (Form 4)
No Form 4 insider trades found for $VTRS.
Key People
No individuals linked to this entity yet.
Political Giving
$88,000 given to 18 candidates across 37 disclosed contributions (FEC Schedule A).
Guy Mr Reschenthaler
Kim Schrier
Kevin Hern
Earl Leroy Carter
Darrell E. Issa
Cliff Bentz
Gerald E. Connolly
Debbie Dingell
Diana Harshbarger
Frank Pallone
Dave McCormick
Mitch McConnell
Elizabeth Fletcher
Dan Newhouse
Laurel Lee
Thomas H. Kean
Neal Patrick Dunn, MD, FACS
James D Jordan
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro